TARS
Tarsus Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.06B
P/E Ratio
—
EPS
$-1.59
Beta
0.63
52W High
$85.25
52W Low
$38.51
50-Day MA
$68.30
200-Day MA
$63.64
Dividend Yield
—
Profit Margin
-14.70%
Forward P/E
106.38
PEG Ratio
—
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Fundamentals
| Revenue (TTM) | $451.36M |
| Gross Profit (TTM) | $356.35M |
| EBITDA | $-69.15M |
| Operating Margin | -5.26% |
| Return on Equity | -23.40% |
| Return on Assets | -9.45% |
| Revenue/Share (TTM) | $10.80 |
| Book Value | $8.07 |
| Price-to-Book | 8.69 |
| Price-to-Sales (TTM) | 6.78 |
| EV/Revenue | 5.85 |
| EV/EBITDA | -3.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 128.40% |
| Shares Outstanding | $42.56M |
| Float | $32.26M |
| % Insiders | 3.14% |
| % Institutions | 107.55% |
Historical Volatility
HV 10-Day
43.31%
HV 20-Day
42.64%
HV 30-Day
40.44%
HV 60-Day
44.12%
HV Rank
31.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($95.11 target)
1
Strong Buy8
BuyData last updated: 4/9/2026